Cargando…

Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2

COVID-19 is the most rapidly growing pandemic in modern time, and the need for serological testing is most urgent. Although the diagnostics of acute patients by RT-PCR is both efficient and specific, we are also crucially in need of serological tools for investigating antibody responses and assessin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Tove, Nissen, Karolina, Krambrich, Janina, Rönnberg, Bengt, Akaberi, Dario, Esmaeilzadeh, Mouna, Salaneck, Erik, Lindahl, Johanna, Lundkvist, Åke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178815/
https://www.ncbi.nlm.nih.gov/pubmed/32363011
http://dx.doi.org/10.1080/20008686.2020.1754538
_version_ 1783525542892404736
author Hoffman, Tove
Nissen, Karolina
Krambrich, Janina
Rönnberg, Bengt
Akaberi, Dario
Esmaeilzadeh, Mouna
Salaneck, Erik
Lindahl, Johanna
Lundkvist, Åke
author_facet Hoffman, Tove
Nissen, Karolina
Krambrich, Janina
Rönnberg, Bengt
Akaberi, Dario
Esmaeilzadeh, Mouna
Salaneck, Erik
Lindahl, Johanna
Lundkvist, Åke
author_sort Hoffman, Tove
collection PubMed
description COVID-19 is the most rapidly growing pandemic in modern time, and the need for serological testing is most urgent. Although the diagnostics of acute patients by RT-PCR is both efficient and specific, we are also crucially in need of serological tools for investigating antibody responses and assessing individual and potential herd immunity. We evaluated a commercially available test developed for rapid (within 15 minutes) detection of SARS-CoV-2-specific IgM and IgG by 29 PCR-confirmed COVID-19 cases and 124 negative controls. The results revealed a sensitivity of 69% and 93.1% for IgM and IgG, respectively, based solely on PCR-positivity due to the absence of a serological gold standard. The assay specificities were shown to be 100% for IgM and 99.2% for IgG. This indicates that the test is suitable for assessing previous virus exposure, although negative results may be unreliable during the first weeks after infection. More detailed studies on antibody responses during and post infection are urgently needed.
format Online
Article
Text
id pubmed-7178815
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-71788152020-05-01 Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 Hoffman, Tove Nissen, Karolina Krambrich, Janina Rönnberg, Bengt Akaberi, Dario Esmaeilzadeh, Mouna Salaneck, Erik Lindahl, Johanna Lundkvist, Åke Infect Ecol Epidemiol Research Article COVID-19 is the most rapidly growing pandemic in modern time, and the need for serological testing is most urgent. Although the diagnostics of acute patients by RT-PCR is both efficient and specific, we are also crucially in need of serological tools for investigating antibody responses and assessing individual and potential herd immunity. We evaluated a commercially available test developed for rapid (within 15 minutes) detection of SARS-CoV-2-specific IgM and IgG by 29 PCR-confirmed COVID-19 cases and 124 negative controls. The results revealed a sensitivity of 69% and 93.1% for IgM and IgG, respectively, based solely on PCR-positivity due to the absence of a serological gold standard. The assay specificities were shown to be 100% for IgM and 99.2% for IgG. This indicates that the test is suitable for assessing previous virus exposure, although negative results may be unreliable during the first weeks after infection. More detailed studies on antibody responses during and post infection are urgently needed. Taylor & Francis 2020-04-14 /pmc/articles/PMC7178815/ /pubmed/32363011 http://dx.doi.org/10.1080/20008686.2020.1754538 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hoffman, Tove
Nissen, Karolina
Krambrich, Janina
Rönnberg, Bengt
Akaberi, Dario
Esmaeilzadeh, Mouna
Salaneck, Erik
Lindahl, Johanna
Lundkvist, Åke
Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2
title Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2
title_full Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2
title_fullStr Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2
title_full_unstemmed Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2
title_short Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2
title_sort evaluation of a covid-19 igm and igg rapid test; an efficient tool for assessment of past exposure to sars-cov-2
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178815/
https://www.ncbi.nlm.nih.gov/pubmed/32363011
http://dx.doi.org/10.1080/20008686.2020.1754538
work_keys_str_mv AT hoffmantove evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2
AT nissenkarolina evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2
AT krambrichjanina evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2
AT ronnbergbengt evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2
AT akaberidario evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2
AT esmaeilzadehmouna evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2
AT salaneckerik evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2
AT lindahljohanna evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2
AT lundkvistake evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2